Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria

References

• KamangarFDoresGMAndersonWFPatterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the worldJ Clin Oncol200624142137215016682732
   PubMed Web of Science ®Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• FedewaSAJemalAProstate cancer disease severity and country of origin among black men in the United StatesProstate Cancer Prostatic Dis201316217618023338555
   PubMed Web of Science ®Google Scholar
• TindallEAMonareLRPetersenDCClinical presentation of prostate cancer in Black South AfricansProstate201474888089124723425
   PubMed Web of Science ®Google Scholar
• SapiraMKObiorahCCAge and pathology of prostate cancer in South-Southern Nigeria; is there a pattern?Med J Malaysia201267441741923082453
   PubMedGoogle Scholar
• UgareUGBasseyIEJibrinPGEkanemIAAnalysis of Gleason grade and scores in 90 Nigerian Africans with prostate cancer during the period 1994 to 2004Afr Health Sci2012121697323066423
   PubMed Web of Science ®Google Scholar
• SchröderFHHugossonJRoobolMJERSPC InvestigatorsScreening and prostate-cancer mortality in a randomized European studyN Engl J Med2009360131320132819297566
   PubMed Web of Science ®Google Scholar
• FaisalFASundiDPierorazioPMOutcomes of men with an elevated PSA as their sole preoperative intermediate or high risk featureBJU Int20141146bE120E12924731026
   PubMed Web of Science ®Google Scholar
• KoieTMitsuzukaKYoneyamaTProstate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high risk prostate cancer who underwent radical prostatectomyInt J Clin Oncol201520117618124771079
   PubMed Web of Science ®Google Scholar
• LarréSAzzouziARCancel-TassinGImpact de l’obésité sur le PSA lors du dépistage du cancer de la prostate. [Impact of obesity on PSA in prostate cancer screening]Prog Urol200717481581817633992
   PubMed Web of Science ®Google Scholar
• WuYSNaRXuJFBaiPDJiangHWDingQThe influence of prostate volume on cancer detection in the Chinese populationAsian J Androl201416348248624625884
   PubMed Web of Science ®Google Scholar
• EpsteinJIAn update of the Gleason grading systemJ Urol2010183243344020006878
   PubMed Web of Science ®Google Scholar
• EpsteinJIAllsbrookWCJrAminMBEgevadLLISUP Grading Committee2005The International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinomaAm J Surg Pathol20052991228124216096414
   PubMed Web of Science ®Google Scholar
• SfoungaristosSKatafigiotisIPerimenisPThe role of prostate density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system eraCan Urol Assoc J2013711–12E722E72724282465
   PubMed Web of Science ®Google Scholar
• GerberGSThistedRAScardinoPTResults of radical prostatectomy in men with clinically localized prostate cancerJAMA199627686156198773633
   PubMed Web of Science ®Google Scholar
• HeidenreichABastianPJBellmuntJEuropean Association of UrologyEAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013Eur Urol201465112413724207135
   PubMed Web of Science ®Google Scholar
• NormanZMilitzaPAndresFIs active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillanceInt Braz J Urol201440215416024856482
   PubMed Web of Science ®Google Scholar
• MochtarCAKiemeneyLAvan RiemsdijkMMProstate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasiaEur Urol200344669570014644122
   PubMed Web of Science ®Google Scholar
• NnabugwuIIUgwumbaFOEnivwenaeOAUdehEIOteneCONnabugwuCASerum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinician’s decision makingClin Interv Aging201510899325565791
   PubMed Web of Science ®Google Scholar
• YamoahKBeechamKHegartySEHyslopTShowalterTYarneyJEarly results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomesBMC Cancer2013132323324165
   PubMed Web of Science ®Google Scholar
• AdewuyiSAMbibuNHSamailaMOKetikuKKDurosinmi-EttiFAClinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006–2009Niger Postgrad Med J2013201455123661210
   PubMedGoogle Scholar
• AntunesAACrippaADall’OglioMFNesrallahLJLeiteKRSrougiMAge impact in clinicopathologic presentation and the clinical evolution of prostate cancer in patients submitted to radical prostatectomyInt Braz J Urol2006321485516519828
   PubMedGoogle Scholar
• YarneyJVanderpuyeVMensahJClinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian menUrol Oncol201331332533021441045
   PubMed Web of Science ®Google Scholar
• ChamieKOberfoellSKwanLLaboJWeiJTLitwinMSBody mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?Urology201381594995523477756
   PubMed Web of Science ®Google Scholar
• PenneyKLStampferMJJahnJLGleason grade progression is uncommonCancer Res201373165163516823946472
   PubMed Web of Science ®Google Scholar
• IzumiKIkedaHMaolakeAThe relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levelsProstate201575101034104225753899
   PubMed Web of Science ®Google Scholar
• MoroteJTrillaEEsquenaSValue of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancerInt J Biol Markers200217423924312521127
   PubMed Web of Science ®Google Scholar
• WalzJHaeseAScattoniVPercent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/ml and lowerCancer2008113102695270318853417
   PubMed Web of Science ®Google Scholar
• FalzaranoSMMagi-GalluzziCProstate cancer staging and grading at radical prostatectomy over timeAdv Anat Pathol201118215916421326013
   PubMed Web of Science ®Google Scholar
• LaveryHJDrollerMJDo Gleason patterns 3 and 4 prostate cancer represent separate disease states?J Urol201218851667167522998919
   PubMed Web of Science ®Google Scholar
• KarademirIShenDPengYProstate volumes derived from MRI volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancerAJR Am J Roentgenol201320151041104824147475
   PubMed Web of Science ®Google Scholar
• van der KwastTHAminMBBillisAISUP Prostate Cancer GroupInternational Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 2: T2 substaging and prostate cancer volumeMod Pathol2011241162520818340
   PubMed Web of Science ®Google Scholar
• VellekoopALoebSFolkvaljonYStattinPPopulation based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancerJ Urol2014191235035724071481
   PubMed Web of Science ®Google Scholar